© 2025 MJH Life Sciences™ and Patient Care Online. All rights reserved.
Latest Conference Articles
New Data Show Rise in Decompensated Cirrhosis and Hepatic Encephalopathy Cases among US Medicare Beneficiaries
November 10th 2023
TLM 2023: Over 15 years, decompensated cirrhosis and OHE notably rose among Medicare beneficiaries with cirrhosis, exceeding 40% and 20% in 2020.
New NAFLD Familial Risk Score Outperforms FIB-4 for Predicting Advanced Fibrosis in First-Degree Relatives
November 10th 2023
TLM 2023: The simple noninvasive tool may be an alternative to FIB-4, researchers said, and the new data may have implications for NAFLD surveillance.
Novel Algorithm, FAST-3, Shows Promise as Noninvasive Classifier for Advanced Fibrosis in MASLD
November 10th 2023
The predictive algorithm uses FibroScan-captured CAP and LSM data plus 5 clinical variables to identify advanced fibrosis in persons with MASLD.
Hepatic Steatosis is a Risk Factor for MACE, Even Among Individuals at Low 10-Year ASCVD Risk
November 10th 2023
TLM 2023: The burden of CAD is similar between persons with hepatic steatosis at low and high ASCVD risk, but rate of MACE is higher in the low-risk population.
Rifaximin Significantly Reduced Recurrent OHE and Associated Health Care Utilization
November 10th 2023
TLM 2023: Use of rifaximin significantly reduced mean number of OHE episodes as well as hospital contacts, including ED visits and admissions.
Statin Protection Against Cirrhosis in Adults with NAFLD More Pronounced with Age
November 10th 2023
TLM 2023: Investigators found that the protective effects of statin therapy against late stage liver disease increased with age older than 51 years.
New Research Reveals Underestimation of Overt Hepatic Encephalopathy Hospitalizations in US
November 10th 2023
TLM 2023: Relying solely on a primary diagnosis for overt hepatic encephalopathy underestimates the actual rate, length of stay, and costs of OHE hospitalizations.
STUDY: Novel “Triagonist” Retatrutide Resolved Steatosis in Over 85% of Patients with MASLD and Obesity
November 10th 2023
TLM 2023: In participants with metabolic dysfunction-associated steatotic liver disease, retatrutide 8 mg and 12 mg resolved steatosis in >85% of subjects.
It's High Time to Retire NAFLD: Multinational Liver Societies Explain
November 8th 2023
NAFLD, a term coined in the mid-nineteenth century but never an accurate name for the diseases it now stands for, was ready to go, agreed international experts.
NAFLD is Now MASLD: The New Nomenclature, At-a-Glance
November 8th 2023
The shift in naming for diseases historically known as nonalcoholic fatty liver disease will be top of mind at The Liver Meeting 2023. Get a quick look at why.